RecruitingPhase 3NCT07563881

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

Sponsor

Rapport Therapeutics Inc.

Enrollment

333 participants

Start Date

Jun 5, 2026

Study Type

INTERVENTIONAL

Conditions

Epilepsy Focal Epilepsy Focal Seizure

Summary

This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Placebo, a drug called RAP-219, and others for people with epilepsy, focal epilepsy, and other related conditions. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRAP-219

RAP-219 high dose tablets administered orally daily

DRUGRAP-219

RAP-219 medium dose tablets administered orally daily

OTHERPlacebo

Matching placebo tablets administered orally daily

Locations(4)

Amicis Research Center

Palmdale, California, United States

Indiana University Health Fort Wayne Neurology

Fort Wayne, Indiana, United States

Mid-Atlantic Epilepsy and Sleep Center

Bethesda, Maryland, United States

Northeast Regional Epilepsy Group

Hackensack, New Jersey, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07563881

Related Trials